Ignite Creation Date:
2024-05-06 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05714202
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2023-01-27
Brief Title:
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin BCG in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer HR-NMIBC
Sponsor:
Janssen Research Development LLC
Organization:
Janssen Research Development LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-23
Start Date Type:
ACTUAL
Primary Completion Date:
2029-09-18
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-09-18
Completion Date Type:
ESTIMATED
First Submit Date:
2023-01-27
First Submit QC Date:
January 27 2023
Study First Post Date:
2023-02-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-08
Last Update Post Date:
2024-06-20
Last Update Post Date Type:
ACTUAL